Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

To assess the extent to which funding and study design are associated with high reprint orders. Case-control study. Top articles by size of reprint orders in seven journals, 2002-09. Lancet, Lancet Neurology, Lancet Oncology (Lancet Group), BMJ, Gut, Heart, and Journal of Neurology, Neurosurgery & Psychiatry (BMJ Group) matched to contemporaneous articles not in the list of high reprint orders. Funding and design of randomised controlled trials or other study designs. Median reprint orders for the seven journals ranged from 3000 to 126,350. Papers with high reprint orders were more likely to be funded by the pharmaceutical industry than were control papers (industry funding versus other or none: odds ratio 8.64, 95% confidence interval 5.09 to 14.68, and mixed funding versus other or none: 3.72, 2.43 to 5.70). Funding by the pharmaceutical industry is associated with high numbers of reprint orders.

Original publication

DOI

10.1136/bmj.e4212

Type

Journal article

Journal

BMJ (Clinical research ed.)

Publication Date

05/09/2012

Volume

344